Ana-Maria Henao-Restrepo

World Health Organization WHO, Islāmābād, Islāmābād, Pakistan

Are you Ana-Maria Henao-Restrepo?

Claim your profile

Publications (4)17.99 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lessons learned from the successful end of endemic measles virus transmission (i.e., elimination) in the United States include the critical roles of strong political commitment, a regionwide initiative, adequate funding, and a broad coalition of partners. Implications of measles elimination in the United States for global measles control and regional elimination efforts include demonstration of the high vaccination coverage and, in turn, population immunity needed for elimination; the importance of accurate monitoring of vaccination coverage at local, state, and national levels; a vaccination strategy that includes at least 2 opportunities for measles immunization; and the essential role of integrated epidemiological and laboratory surveillance. The United States, with a population of 288 million, is, to our knowledge, the largest country to have ended endemic measles transmission. This experience provides evidence that sustained interruption of transmission can be achieved in large geographic areas, suggesting the feasibility of global eradication of measles.
    The Journal of Infectious Diseases 06/2004; 189 Suppl 1(s1):S251-7. DOI:10.1086/378092 · 6.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Measles remains a major cause of mortality with an estimated 745,000 deaths in 2001. The timely, sustained, and uninterrupted supply of affordable vaccines is critical for global efforts to reduce measles mortality. The measles vaccine supply needs to be considered in the context of vaccine security. In 2000, the World Health Organization (WHO) and United Nations Children's Fund (UNICEF) issued a number of new recommendations for measles control that resulted in a two-fold increase in the number of measles-containing vaccine (MCV) doses administered between 2000 and 2002. Any additional increments in mass campaigns must be duly planned and have time lines so that vaccine production capacities are increased to optimal levels. The cornerstone of vaccine security efforts remains at the country level. WHO and UNICEF, with major partners, will review progress on measles mortality reduction and assess the feasibility of global measles eradication. Strong collaboration by all key stakeholders will be invaluable.
    The Journal of Infectious Diseases 06/2003; 187 Suppl 1:S22-8. DOI:10.1086/368274 · 6.00 Impact Factor
  • Ana-Maria Henao-Restrepo · Peter Strebel · Edward John Hoekstra · Maureen Birmingham · Julian Bilous ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Worldwide during the 1980s remarkable progress was made in controlling measles through increasing routine measles vaccination to nearly 80%. In 2000, an estimated 777,000 measles deaths occurred, of which 452,000 were in the African Region of the World Health Organization (WHO). In 2001, WHO and the United Nations Children's Fund published a 5-year strategic plan to reduce measles mortality by half by 2005. Strategies include providing a second opportunity for measles immunization to all children through nationwide supplementary immunization activities, increasing routine vaccination coverage, and improving surveillance with laboratory confirmation of suspected measles cases. In 2000, over 100 million children received a dose of measles vaccine through supplementary immunization activities, a number projected to increase during 2002-2005. Current systems for monitoring measles vaccination coverage and disease burden must be improved to accurately assess progress toward measles control goals.
    The Journal of Infectious Diseases 06/2003; 187 Suppl 1(s1):S15-21. DOI:10.1086/368273 · 6.00 Impact Factor
  • Source
    Maria Teresa Aguado · Ana-Maria Henao-Restrepo ·
    [Show abstract] [Hide abstract]
    ABSTRACT: This chapter reviews the case for new, needle-free measles vaccine delivery devices and new vaccine formulations. It focuses primarily on such needle-free vaccine delivery devices as jet injectors for delivering parenteral measles vaccine, and on alternative routes for measles mucosal immunization (aerosoldelivered and nasal vaccines). It also outlines the optimal profile for new products, summarizes the state of the art of these products, and considers their suitability and practicality for use in measles immunization programs, particularly in developing countries. Finally, this chapter presents an update on a special project that has been designated a high priority for WHO—the Measles Aerosol Project-. This is a chapter included in Vaccines. Preventing Disease and Protecting Health, a book that celebrates the ways in which vaccines have played a role in improving the health of the world's populations.